Table 3.

Analysis of the determinants of developing an ADR after taking an antimalarial

Variables	Total no. of patients (%)	Unadjusted OR	95% CI	p value	Adjusted OR	95% CI	p value
Total	782
Age groups, years
0–18	324 (41.4)	1.0	–	–	–	–	–
≥ 19	458 (58.6)	1.9	1.3–2.8	0.00	1.5	0.9–2.5	0.09
Sex
Male	324 (41.4)	1.0	–	–
Female	458 (58.6)	1.1	0.7–1.4	0.87	1.8	1.1–2.9	0.03
Facility type
Public	759 (93.2)	1.0	–	–
Private	23 (2.9)	1.2	0.5–3.2	0.68	2.117	0.6–7.3	0.24
Residence
Iganga/Mayuge	456 (58.3)	1.0	–	–
Kampala	326 (41.7)	7.1	4.4–11.3	0.00	9.9	5.4–17.9	0.00
Diagnostic test results
Negative	41 (5.2)	1.0	–	–	–	–	–
Positive	556 (71.1)	1.7	0.8–3.5	0.13	1.5	0.6–3.4	0.36
No test performed	185 (23.7)	1.3	0.03–2.9	0.42	3.8	1.7–6.2	0.21
Antimalarial drugs
Other antimalarials	21 (2.7)	1.0
First-line ACTs	761 (97.3)	1.8	0.5–6.1	0.37	2.4	0.4–14.3	0.32
Comorbidities
No	448 (57.3)	1.0	–	–	–	–	–
Yes	334 (42.7)	8.6	5.7–12.9	0.00	7.4	4.4–12.3	0.00

OR odds ratio, ADR adverse drug reaction, ACT artemisinin-based combination therapy, CI confidence interval